Details for Patent: 11,504,333

« Back to Dashboard

Which drugs does patent 11,504,333 protect, and when does it expire?

Patent 11,504,333 protects TAFINLAR and is included in one NDA.

Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 11,504,333

Title:	Pharmaceutical composition
Abstract:	The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.
Inventor(s):	Nikos KARANIKOLOPOULOS, Paul Anthony GOULDING
Assignee:	Novartis AG
Application Number:	US16/628,463
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 11,504,333

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes					Y

International Family Members for US Patent 11,504,333

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018297656
Australia	2021221451
Australia	2023266278